Literature DB >> 32246844

Determination of toosendanin and trans-anethole in Fructus Meliae Toosendan and Fructus Foeniculi by HPLC-MS/MS and GC-MS/MS in rat plasma and their potential herb-herb interactions.

Jiaoyan Yu1, Ruitao Zhang1, Tian Zhang1, Jun Zhao1, Yang Zhang1, Qingwei Wang1, Linna Liu1, Yuan Xu1, Lei Shi1.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: The objective of traditional Chinese medicine (TCM) combination theory is to "reduce toxicity and increase efficiency", especially to solve the liver toxicity of many TCMs. Fructus Meliae Toosendan (CLZ)-Fructus Foeniculi (XHX) is a typical traditional Chinese herb pair that decreases the toxicity and increases the efficiency of the herbs. Fructus Meliae Toosendan (CLZ, cold-natured) has significant liver toxicity. However, it has been widely used in combination with Fructus Foeniculi (XHX, hot-natured) for thousands of years in TCM, in which form it shows no hepatotoxicity, indicating that the combined use of XHX and CLZ can reduce the hepatotoxicity of CLZ. Herb-herb interactions could affect herb pharmacokinetics and in vivo efficacy. The herb-herb interactions between CLZ and XHX are still unknown.
MATERIALS AND METHODS: This study used liquid chromatography tandem mass spectrometry (LC-MS) and gas chromatography tandem mass spectrometry (GC-MS) to establish methods for detecting toosendanin and trans-anethole, the main active substances of CLZ and XHX, respectively. Additionally, we investigated their herb-herb interactions via pharmacokinetic and pharmacodynamic studies.
RESULTS: The results indicate that the established analytical methods are suitable for detecting toosendanin and trans-anethole, and the methodology meets the requirements of biological sample testing methods. Compared with the CLZ group, the pharmacokinetic parameters Cmax , AUC(0-t) , AUC(0-∞) , MRT(0-t) and MRT(0-∞) of toosendanin in the CLZ-XHX group notably decreased and the values of Vz/F remarkably increased. Compared with the XHX group, the pharmacokinetic parameters Cmax , AUC0-t , AUC0-∞, Tmax and t1/2z of trans-anethole notably increased in the CLZ-XHX group, and the values of CLz/F and Vz/F obviously decreased.
CONCLUSION: The pharmacokinetic results indicate that XHX can significantly decrease the absorption and bioavailability and accelerate the elimination process of toosendanin in CLZ. XHX could decrease the risk of in vivo accumulation of the toxic constituent of CLZ, toosendanin, thus decreasing its toxicity. It has also been shown that CLZ can significantly increase absorption and bioavailability and attenuate the elimination process of trans-anethole in XHX, thus enhancing its efficacy. Hepatotoxicity studies indicate that CLZ has significant hepatotoxicity, and its combined use with XHX can decrease its liver-damaging properties.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  GC-MS; HPLC-MS; attenuated toxicity; herb-herb interactions; pharmacokinetics; synergistic effects

Mesh:

Substances:

Year:  2020        PMID: 32246844     DOI: 10.1002/bmc.4837

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  3 in total

Review 1.  Limonoids From the Genus Melia (Meliaceae): Phytochemistry, Synthesis, Bioactivities, Pharmacokinetics, and Toxicology.

Authors:  Wenxiang Fan; Linhong Fan; Zhengtao Wang; Li Yang
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

2.  [Rapid analysis of serum components and metabolites of Sanzi San by high performance liguid chromatography-quadrupole/ electrostatic field orbitrap high resolution mass spectrometry].

Authors:  Huiwen Zhang; Huimin Xia; Hong Liu; Yanyan Liu; Xin Jiu; Minhui Zhang; Chunlong He; Huanyun Wang
Journal:  Se Pu       Date:  2022-07

Review 3.  Herbal Medicines Targeting the Improved β-Cell Functions and β-Cell Regeneration for the Management of Diabetes Mellitus.

Authors:  Akurange Sujeevi Dammadinna Wickramasinghe; Pabasara Kalansuriya; Anoja Priyadarshani Attanayake
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-14       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.